292
Participants
Start Date
August 19, 2015
Primary Completion Date
May 8, 2018
Study Completion Date
May 8, 2018
ramosetron, aprepitant, dexamethasone
ramosetron 0.3 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
palonosetron, aprepitant, dexamethasone
palonosetron 0.25 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
St. Vincent'S Hospital, Suwon
Keimyung University Dongsan Medical Center, Daegu
Chungnam National University Hospita, Daejeon
Pusan National University Hospital, Pusan
Kangbuk Samsung Hospital, Seoul
Kangdong Sacred Heart Hospital, Seoul
Samsung Medical Center, Seoul
Seoul St. Mary's Hospital, Seoul
Severance Hospital, Seoul
Ajou University Hospital, Suwon
The Catholic University of Korea
OTHER
Astellas Pharma Korea, Inc.
INDUSTRY
Kangdong Sacred Heart Hospital
OTHER